While AstraZeneca's (NYSE:AZN) stock delivered solid returns in 2013, the company is still in the middle of a multiyear turnaround. With patent expirations just around the corner, and a pipeline that has failed to deliver a new blockbuster therapy in recent years, AstraZeneca's strategy has become the most important factor in its long-term survival in the pharmaceutical industry.
This massive company has several moving parts. But in the video below, Motley Fool analyst Max Macaluso focuses on just one red light and one green light that investors should consider before buying shares today.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.